CoChat

Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance, not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different "hot spots," were gain of function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole resistance but that they can also confer a selective advantage under host conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1000268

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata azole-resistant isolates from groups of sequential clinical isolates. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to the azole-susceptible parental strains (set at 1.00). Error bars show standard deviations.
Figure 1 Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata azole-resistant isolates from groups of sequential clinical isolates. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to the azole-susceptible parental strains (set at 1.00). Error bars show standard deviations.CC BY · PubMed Central
Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.
Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.CC BY · PubMed Central
Figure 3 Expression of CgPDR1 in matched pairs of azole-susceptible (S) and azole-resistant (R) isolates. RNA was isolated from log phase cultures, slot-blotted to membranes and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1. Expression values represent the increase of CgPDR1 expression in azole-resistant isolates relative to their azole-susceptible parental strains. RNA was also used for real-time quantitative RT-PCR as described in Material and Methods. Values given on the right diagram are means (±SEM) of three separate experiments and express CgPDR1 relative expression in resistant isolates as compared to their matched susceptible parents.
Figure 3 Expression of CgPDR1 in matched pairs of azole-susceptible (S) and azole-resistant (R) isolates. RNA was isolated from log phase cultures, slot-blotted to membranes and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1. Expression values represent the increase of CgPDR1 expression in azole-resistant isolates relative to their azole-susceptible parental strains. RNA was also used for real-time quantitative RT-PCR as described in Material and Methods. Values given on the right diagram are means (±SEM) of three separate experiments and express CgPDR1 relative expression in resistant isolates as compared to their matched susceptible parents.CC BY · PubMed Central
Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).
Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).CC BY · PubMed Central
Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.
Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.CC BY · PubMed Central
Figure 6 Reconstitution of CgPDR1 GOF alleles in C. glabrata. (A) Fluconazole susceptibility testing of DSY562 pdr1Δ mutant strain (SFY93) expressing different CgPDR1 alleles, which were named according to their strain number origin and by indicating the amino acid substitution (in superscript) associated with a specific strain number. The following strains correspond to the indicated genotypes: DSY562 pdr1Δ+486:SFY98; 489L328F: SFY99; 738: SFY100; 739R376W: SFY101; 2253: SFY102; 2254D1082G:SFY103; 2235: SFY104; 2234T588A: SFY105; 701: SFY106; 704T607S: SFY107; 529:SFY108; 530E1083Q: SFY109; 753: SFY110; 754Y584C: SFY111; 726: SFY112; 727D876Y: SFY113; BPY55P882L: SFY116. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in the DSY562 pdr1Δ mutant strain (SFY93) expressing different CgPDR1 alleles, named according to their strain number origin. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations.
Figure 6 Reconstitution of CgPDR1 GOF alleles in C. glabrata. (A) Fluconazole susceptibility testing of DSY562 pdr1Δ mutant strain (SFY93) expressing different CgPDR1 alleles, which were named according to their strain number origin and by indicating the amino acid substitution (in superscript) associated with a specific strain number. The following strains correspond to the indicated genotypes: DSY562 pdr1Δ+486:SFY98; 489L328F: SFY99; 738: SFY100; 739R376W: SFY101; 2253: SFY102; 2254D1082G:SFY103; 2235: SFY104; 2234T588A: SFY105; 701: SFY106; 704T607S: SFY107; 529:SFY108; 530E1083Q: SFY109; 753: SFY110; 754Y584C: SFY111; 726: SFY112; 727D876Y: SFY113; BPY55P882L: SFY116. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in the DSY562 pdr1Δ mutant strain (SFY93) expressing different CgPDR1 alleles, named according to their strain number origin. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations.CC BY · PubMed Central
Figure 7 C. glabrata tissue burdens in murine infection models. (A) Fungal tissue burdens in kidneys from immuno-competent BALB/c mice infected intravenously with 4×107 viable cells of C. glabrata strains. Mice were sacrificed at day 7 post-infection; and results, which are expressed as CFUs per gram of tissue, represent values recorded separately for each of the ten mice. Geometric means are indicated by horizontal bars and asterisks indicate statistically significant differences (*: P<0.05; **: P<0.01; ***: P<0.001). NS indicates no significance (P>0.05). The origin of each strain is indicated. Strain background (DSY562 or DSY565) is indicated by filled or empty symbols, respectively. The pdr1Δ mutants from strains DSY562 and DSY565 correspond to SFY92 and SFY94, respectively. Revertants constructed from pdr1Δ mutants are indicated by the re-introduced GOF mutation or by the re-introduced wild type CgPDR1 allele from DSY562. Prism 5.0 was used for statistical analysis and data were processed with non-parametric Wilocoxon Rank sum tests. Comparisons are indicated in the Figure (see Table S3 for details) and associate selected data points. (B) Fungal tissue burdens in kidneys from immuno-suppressed mice infected intravenously with 4×107 viable cells of C. glabrata strains. BALB/c mice were rendered neutropenic by intraperitoneal administration of cyclophosphamide (200 mg kg−1 of body weight per day) three days before challenge and on the day of infection. Mice were sacrificed at day 7 post-infection.
Figure 7 C. glabrata tissue burdens in murine infection models. (A) Fungal tissue burdens in kidneys from immuno-competent BALB/c mice infected intravenously with 4×107 viable cells of C. glabrata strains. Mice were sacrificed at day 7 post-infection; and results, which are expressed as CFUs per gram of tissue, represent values recorded separately for each of the ten mice. Geometric means are indicated by horizontal bars and asterisks indicate statistically significant differences (*: P<0.05; **: P<0.01; ***: P<0.001). NS indicates no significance (P>0.05). The origin of each strain is indicated. Strain background (DSY562 or DSY565) is indicated by filled or empty symbols, respectively. The pdr1Δ mutants from strains DSY562 and DSY565 correspond to SFY92 and SFY94, respectively. Revertants constructed from pdr1Δ mutants are indicated by the re-introduced GOF mutation or by the re-introduced wild type CgPDR1 allele from DSY562. Prism 5.0 was used for statistical analysis and data were processed with non-parametric Wilocoxon Rank sum tests. Comparisons are indicated in the Figure (see Table S3 for details) and associate selected data points. (B) Fungal tissue burdens in kidneys from immuno-suppressed mice infected intravenously with 4×107 viable cells of C. glabrata strains. BALB/c mice were rendered neutropenic by intraperitoneal administration of cyclophosphamide (200 mg kg−1 of body weight per day) three days before challenge and on the day of infection. Mice were sacrificed at day 7 post-infection.CC BY · PubMed Central
Figure 8 Virulence of C. glabrata is dependent on CgPDR1 GOF mutations. (A) Survival curves of mice infected with DSY562 and DSY565 and derived mutants and revertants. Statistical differences were performed using the Log-rank Mantel-Cox test (Prism 5.0) by comparing survival curves of mice infected by DSY562 and by other strains as indicated. The range of significant P values obtained is indicated for DSY565 and strains containing the CgPDR1 allele with a L280F substitution. (B) Survival curves of mice infected with DSY562 and DSY565 and strains reconstituted with different CgPDR1 alleles. The range of significant P values obtained is indicated for DSY565 and strains containing GOF mutations.
Figure 8 Virulence of C. glabrata is dependent on CgPDR1 GOF mutations. (A) Survival curves of mice infected with DSY562 and DSY565 and derived mutants and revertants. Statistical differences were performed using the Log-rank Mantel-Cox test (Prism 5.0) by comparing survival curves of mice infected by DSY562 and by other strains as indicated. The range of significant P values obtained is indicated for DSY565 and strains containing the CgPDR1 allele with a L280F substitution. (B) Survival curves of mice infected with DSY562 and DSY565 and strains reconstituted with different CgPDR1 alleles. The range of significant P values obtained is indicated for DSY565 and strains containing GOF mutations.CC BY · PubMed Central
Figure 9 Fitness assays between azole-resistant and azole-susceptible isolates. (A) In vitro fitness assays. Strains SFY114 (DSY562 pdr1Δ-PDR1) and SFY115 (DSY562 pdr1Δ-L280F) were inoculated in YEPD in single or mixed (1∶1) cultures. Aliquots were taken from each culture in triplicate and population ratios were calculated from the proportion of azole-susceptible and azole-resistant colonies plated onto YEPD agar as described in Material and Methods. (B) In vivo fitness assays. SFY114 (DSY562 pdr1Δ-PDR1) and SFY115 (DSY562 pdr1Δ-L280F) were inoculated intravenously as single or mixed (1∶1) cultures to three groups of mice as described in Material and Methods. Kidneys were taken at given time points from sacrificed mice and population ratios were measured as described above.
Figure 9 Fitness assays between azole-resistant and azole-susceptible isolates. (A) In vitro fitness assays. Strains SFY114 (DSY562 pdr1Δ-PDR1) and SFY115 (DSY562 pdr1Δ-L280F) were inoculated in YEPD in single or mixed (1∶1) cultures. Aliquots were taken from each culture in triplicate and population ratios were calculated from the proportion of azole-susceptible and azole-resistant colonies plated onto YEPD agar as described in Material and Methods. (B) In vivo fitness assays. SFY114 (DSY562 pdr1Δ-PDR1) and SFY115 (DSY562 pdr1Δ-L280F) were inoculated intravenously as single or mixed (1∶1) cultures to three groups of mice as described in Material and Methods. Kidneys were taken at given time points from sacrificed mice and population ratios were measured as described above.CC BY · PubMed Central
Figure 10 Efficacy of azole treatment in C. glabrata assessed by fungal tissue burden in kidneys. Fluconazole (100 mg/Kg/day) was administered by intraperitoneal injection in immuno-suppressed mice as described in Material and Methods. Treatment was initiated 24 h after inoculation (day 1 post-infection) and continued until day 7 post-infection. Mice were injected with 4×107 CFU of each investigated strain and organ homogenates were obtained from ten mice per group that were sacrificed and necropsied on day 8 post-infection. Results, which are expressed as CFUs per gram of tissue, represent means of values recorded separately for each of the mice. Geometric means are indicated by horizontal bars and asterisks indicate statistically significant differences between two conditions (see legend of Figure 7 and Table S3 for details). Closed and empty circles indicate CFU from untreated and fluconazole-treated animals infected with a DSY562 background, respectively. Closed and empty diamonds indicate CFU from untreated and fluconazole-treated isolates with a DSY565 background, respectively.
Figure 10 Efficacy of azole treatment in C. glabrata assessed by fungal tissue burden in kidneys. Fluconazole (100 mg/Kg/day) was administered by intraperitoneal injection in immuno-suppressed mice as described in Material and Methods. Treatment was initiated 24 h after inoculation (day 1 post-infection) and continued until day 7 post-infection. Mice were injected with 4×107 CFU of each investigated strain and organ homogenates were obtained from ten mice per group that were sacrificed and necropsied on day 8 post-infection. Results, which are expressed as CFUs per gram of tissue, represent means of values recorded separately for each of the mice. Geometric means are indicated by horizontal bars and asterisks indicate statistically significant differences between two conditions (see legend of Figure 7 and Table S3 for details). Closed and empty circles indicate CFU from untreated and fluconazole-treated animals infected with a DSY562 background, respectively. Closed and empty diamonds indicate CFU from untreated and fluconazole-treated isolates with a DSY565 background, respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

Items 101–200 of 291

Metadata

Authors
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D.
Affiliations
  • University of Lausanne (CH)
  • Università Cattolica del Sacro Cuore (IT)
  • GATC Biotech (Germany) (DE)
  • Universitätsmedizin Göttingen (DE)
Corresponding author
Sanglard, Dominique
Venue
PLoS Pathogens
Published
2009-01-16
Volume
5
Issue
1
Pages
e1000268
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W2133189384
Cited by
295
References
46
Citations by year
2026: 13 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 19 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 25 · 2017: 19 · 2016: 17 · 2015: 12 · 2014: 22 · 2013: 18 · 2012: 14
FWCI
12.61
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • IRIS (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
  • GRO (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
Candida glabrata, gain-of-function mutations, azole resistance, antifungal resistance, virulence, ABC transporters, transcription factors, clinical isolates, host fitness, trans-acting regulation
MeSH terms
Animals, Candidiasis, Female, Humans, Mice, Inbred BALB C, Mutation, Transcription Factors, Virulence, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Amino Acid Substitution, Drug Resistance, Fungal, Candida glabrata, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.